<DOC>
	<DOC>NCT00634621</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.</brief_summary>
	<brief_title>Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Patients over 18 years of age. Patients of either sex. Patients with documented or highly suspected noninvasive bladder cancer. Patients with hypersensitivity to the drug substance or any excipient of Hexvix. Patients with porphyry. Women of childbearing age. Patients at a high risk of suffering extensive bladder inflammation e.g. patients after intravesical BCG treatment, patients with moderate or severe leukocyturia or patients undergoing recent bladder surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Bladder</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cystoscopy</keyword>
	<keyword>Hexaminolevulinate</keyword>
	<keyword>Hexvix</keyword>
</DOC>